{"id":"0b4561b53993","type":"article","url":"https://hartvaat.nl/2018/04/07/2017-esc-eas-praktische-gids-voor-pcsk9-remming/","title":"2017 ESC/EAS praktische gids voor PCSK9-remming","title_en":"2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"European heart journal","doi":"10.1093/eurheartj/ehx549","source_url":"https://doi.org/10.1093/eurheartj/ehx549","authors":["Ulf Landmesser","M John Chapman","Jane K Stock","Pierre Amarenco","Jill J F Belch","Jan Borén","Michel Farnier","Brian A Ference","Stephan Gielen","Ian Graham","Diederick E Grobbee","G Kees Hovingh","Thomas F Lüscher","Massimo F Piepoli","Kausik K Ray","Erik S Stroes","Olov Wiklund","Stephan Windecker","Jose Luis Zamorano","Fausto Pinto","Lale Tokgözoglu","Jeroen J Bax","Alberico L Catapano"],"significance":8,"published":"2018-04-07","source_date":"2018-04-07","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/"],"congress":"","summary_en":"The 2017 ESC/EAS practical guidance update for PCSK9 inhibitor therapy integrated results from FOURIER and ODYSSEY OUTCOMES to provide clinicians with practical recommendations on patient selection, treatment initiation, and monitoring for PCSK9 inhibitor therapy.","created":"2026-07-03T10:27:13Z","updated":"2026-07-03T13:26:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Geactualiseerde ESC/EAS praktische gids voor PCSK9-remming in de klinische praktijk. Integreert FOURIER- en ODYSSEY OUTCOMES-resultaten.","abstract_original":""}